WuXi Biologics guns for $500M Hong Kong IPO

The Chinese CRO WuXi Biologics has seen strong revenues in recent years.

The big China CRO WuXi Biologics is slated for an initial public offering of up to $513 million in Hong Kong.

According to Thomson Reuters, quoting anonymous people "close to the deal,” the booming contract research organization is said to be offering 193 million shares worth between HK$18.60 to HK$20.60 each, valuing the total deal at up to HK$3.98 billion ($513 million). WuXi has not commented on the reports.

Over a year ago, and a few months after taking the company private in a $3.3 billion deal, WuXi CEO Ge Li has was said to be looking to spin out its biologics unit in an IPO that would value the business at $1.5 billion, according to a report from Bloomberg.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Back in January, it posted new legal documents (PDF) confirming its IPO intentions, but with no financial or value details. It did, however, show strong revenue growth and a list of biopharma partners that include AstraZeneca, Roche, Tesaro and J&J.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.